Novo Suspended by UK Pharma Group Over Weight Drug Marketing
- Drugmaker breached code of conduct with training, group says
- Decision comes as Novo prepares to launch Wegovy in the UK
The Novo Nordisk headquarters in Bagsvaerd outside of Copenhagen.
Photographer: Lislotte Sabroe/AFP/Getty Images
This article is for subscribers only.
The UK pharmaceutical industry association suspended Novo Nordisk A/S for two years over its marketing of a weight-loss drug, saying the company breached the industry’s code of conduct.
Novo failed to make clear its involvement in a training on weight-loss drugs that was offered to pharmacists on LinkedIn, according to the Association of the British Pharmaceutical Industry.